Kelulut Honey for Allergic Conjunctivitis and Dry Eye Symptoms

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorUniversiti Sains Malaysia

About this trial

The goal of this clinical trial is to learn if oral Kelulut honey works to improve eye symptoms in adults with allergic conjunctivitis. It will also look at how safe Kelulut honey is when taken as a daily supplement.

The main questions it aims to answer are:

1. Does oral Kelulut honey reduce itchy, red, watery eyes and dry eye symptoms in people with allergic conjunctivitis? 2. Does oral Kelulut honey improve tear film stability and the health of conjunctival goblet cells (special cells on the eye surface that help keep the eye moist)? 3. What side effects or medical problems do participants have when taking Kelulut honey?

Researchers will compare oral Kelulut honey to a honey-flavoured placebo syrup (a look-alike drink that does not contain Kelulut honey) to see if Kelulut honey is more effective than placebo for treating eye symptoms in allergic conjunctivitis.

Participants will:

1. Take either oral Kelulut honey or a honey-flavoured placebo syrup every day for 1 month 2. Continue their usual treatment for allergic conjunctivitis and dry eye disease as prescribed by their eye doctor 3. Attend clinic visits for eye check-ups, including tests of tear film stability, dry eye symptoms, and eye surface health 4. Answer questionnaires about their eye symptoms and how these affect their daily activities and vision-related quality of life

Participation is voluntary, and participants may stop taking part in the study at any time. Data collected up to the time they withdraw may still be used for research, but their routine medical care will not be affected

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Kelulut Honey 60 g Oral Supplement
  • Kelulut Honey 120 g Oral Supplement
  • Honey-Flavoured Zero-Calorie Syrup (Placebo)

Treatment groups

72 Participants
are divided into 3 treatment groups

Sponsors and collaborators